SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa

Jefferies initiated coverage of Kenvue with a rating of Buy and set a new price target of $27.00

RBC Capital Mkts downgraded Kenvue from Outperform to Sector Perform and set a new price target of $24.00

Citigroup resumed coverage of Kenvue with a rating of Neutral and set a new price target of $21.00

Bernstein initiated coverage of Kenvue with a rating of Underperform and set a new price target of $18.00

William Blair initiated coverage of Kenvue with a rating of Mkt Perform

Goldman resumed coverage of Kenvue with a rating of Neutral and set a new price target of $20.00

Piper Sandler initiated coverage of Kenvue with a rating of Neutral and set a new price target of $20.00

Deutsche Bank upgraded Kenvue from Hold to Buy and set a new price target of $27.00

Canaccord Genuity initiated coverage of Kenvue with a rating of Buy and set a new price target of $28.00

Argus initiated coverage of Kenvue with a rating of Hold

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

3 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its third quarter 2024 financial results before market open on November 7, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage,

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue's common stock. This quarterly dividend is payable on November 27, 2024, to shareholders of record as of the close of business on November 13, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe

Net Sales of $4.0 Billion decreased 0.3%; Organic Growth1 was +1.5% Diluted EPS was $0.03; Adjusted Diluted EPS1 was $0.32 Productivity gains fuel accelerated investment in brands for future growth Reaffirms Outlook for FY24 Net Sales Growth and Adjusted Diluted EPS Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal second quarter ended June 30, 2024. "We are on track to deliver the financial targets we set for 2024, and while we are in the early days, our work to transform Kenvue into a bolder, more agile organization focused on profitable growth is producing results," said Thibaut Mongon, Chief Executive Officer. "With the progress we ha

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced a 2.5% increase in the Company's quarterly dividend as its Board of Directors declared a $0.205 per share dividend on Kenvue common stock payable in the third quarter of 2024. This is a testament to the Company's commitment to return cash to shareholders as part of its capital allocation strategy designed to enable sustainable growth and optimize total shareholder return. The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health c

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its financial results for the second quarter ending June 30, 2024, before market open on August 6, 2024. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more

Q1'24: Net Sales Increased 1.1% to $3.9 Billion with Organic Growth1 of 1.9% Q1'24: Diluted Earnings per Share of $0.15; Adjusted Diluted Earnings per Share1 of $0.28 Reaffirms Fiscal Year 2024 Outlook Kenvue Inc. (NYSE:KVUE) ("Kenvue"), today announced financial results for the fiscal first quarter ended March 31, 2024. "We entered 2024 with clear strategic priorities to reach more consumers, reinvent our ways of working to invest more behind our brands, and to foster a culture that rewards performance and impact," said Thibaut Mongon, Chief Executive Officer. "We began executing against these priorities during the quarter, enabling a solid start to the year and advancing Kenvue fo

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the second quarter of $0.20 per share on the Company's common stock. The second quarter dividend is payable on May 22, 2024 to shareholders of record as of the close of business on May 8, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals aro

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results. The conference call can be accessed by dialing 888-672-2415 from the U.S. or +1 646-307-1952 from international locations. The conference ID for all callers is 14840. A live webcast of the conference call will be available at investors.kenvue.com. A replay will be available after the live event. About Kenvue Kenvue is the world's largest pure-play consumer heal

FY'23: Net Sales Increased 3.3% to $15.4 billion with Organic Growth1 of 5.0% FY'23: Diluted Earnings per Share of $0.90; Adjusted Diluted Earnings per Share1 of $1.29 Q4'23: Net Sales Decreased (2.7)% to $3.7 billion with Organic Growth1 of (2.4)% Q4'23: Diluted Earnings per Share of $0.17; Adjusted Diluted Earnings per Share1 of $0.31 Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023. "2023 was a transformational year for Kenvue as we began delivering on our long-term value creation algorithm centered around profitable growth,

Kenvue Inc. (NYSE:KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company's common stock. The first quarter dividend is payable on February 28, 2024 to shareholders of record as of the close of business on February 14, 2024. About Kenvue Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professi

The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024.

Throughout the last three months, 4 analysts have evaluated Kenvue (NYSE:KVUE), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 0 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $21.0, along with a high estimate of $22.00 and a low estimate of $20.00. Observing a downward trend, the

JP Morgan analyst Andrea Teixeira maintains Kenvue (NYSE:KVUE) with a Overweight and lowers the price target from $23 to $22.

Citigroup analyst Filippo Falorni maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $21 to $20.

Sanofi SA (NASDAQ:SNY) is calling for initial bids for its $20 billion consumer health division. The French pharmaceutical giant is also considering a potential public listing. Potential suitors must submit first-round bids by mid-July, Bloomberg reports. Advent International and France’s PAI Partners both expressed interest in acquiring the division, which includes over-the-counter products such as Phytoxil cough syrups and Icy Hot pain relief gels. PAI is the sole French bidder and might need to find partners to manage the transaction’s scale. Other major firms considering bids include Blackstone Inc (NYSE:BX), Clayton Dubilier & Rice, CVC Capital Partners Plc, and TPG Inc.

Kenvue's (NYSE:KVUE) short percent of float has risen 34.48% since its last report. The company recently reported that it has 37.30 million shares sold short, which is 1.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.36 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im

5 analysts have expressed a variety of opinions on Kenvue (NYSE:KVUE) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 1 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 1 0 3M Ago 0 0 2 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.0, along with a high estimate of $21.00 and a low estimate of $18.00. A 9.09% drop is evident i

Citigroup analyst Filippo Falorni reinstates Kenvue (NYSE:KVUE) with a Neutral and announces $21 price target.

Kenvue's (NYSE:KVUE) short percent of float has fallen 23.28% since its last report. The company recently reported that it has 27.80 million shares sold short, which is 1.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is i

On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ:SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 million, to enhance its facilities at its French manufacturing facility in Dunkirk. Pfizer pledged even more, making a commitment to invest 500 million euros or $540 million over the next five years to bo